Logo image of TNXP

TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Fundamental Analysis

NASDAQ:TNXP - Nasdaq - US8902608392 - Common Stock - Currency: USD

40.87  -1.49 (-3.52%)

After market: 40.64 -0.23 (-0.56%)

Fundamental Rating

4

Overall TNXP gets a fundamental rating of 4 out of 10. We evaluated TNXP against 557 industry peers in the Biotechnology industry. While TNXP has a great health rating, there are worries on its profitability. TNXP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TNXP has reported negative net income.
TNXP had a negative operating cash flow in the past year.
TNXP had negative earnings in each of the past 5 years.
In the past 5 years TNXP always reported negative operating cash flow.
TNXP Yearly Net Income VS EBIT VS OCF VS FCFTNXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -68.40%, TNXP is doing worse than 63.20% of the companies in the same industry.
The Return On Equity of TNXP (-73.13%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -68.4%
ROE -73.13%
ROIC N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
TNXP Yearly ROA, ROE, ROICTNXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Gross Margin of TNXP (29.81%) is better than 73.79% of its industry peers.
The Profit Margin and Operating Margin are not available for TNXP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNXP Yearly Profit, Operating, Gross MarginsTNXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
TNXP has more shares outstanding than it did 1 year ago.
TNXP has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TNXP has been reduced compared to a year ago.
TNXP Yearly Shares OutstandingTNXP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
TNXP Yearly Total Debt VS Total AssetsTNXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 9.16 indicates that TNXP is not in any danger for bankruptcy at the moment.
The Altman-Z score of TNXP (9.16) is better than 84.56% of its industry peers.
TNXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.16
ROIC/WACCN/A
WACC9.96%
TNXP Yearly LT Debt VS Equity VS FCFTNXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

TNXP has a Current Ratio of 12.31. This indicates that TNXP is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TNXP (12.31) is better than 83.66% of its industry peers.
A Quick Ratio of 11.64 indicates that TNXP has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 11.64, TNXP belongs to the best of the industry, outperforming 82.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.31
Quick Ratio 11.64
TNXP Yearly Current Assets VS Current LiabilitesTNXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

TNXP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.94%, which is quite impressive.
Looking at the last year, TNXP shows a decrease in Revenue. The Revenue has decreased by -2.05% in the last year.
EPS 1Y (TTM)88.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.51%
Revenue 1Y (TTM)-2.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-2.14%

3.2 Future

The Earnings Per Share is expected to grow by 25.99% on average over the next years. This is a very strong growth
Based on estimates for the next years, TNXP will show a very strong growth in Revenue. The Revenue will grow by 118.28% on average per year.
EPS Next Y99.47%
EPS Next 2Y41.33%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year-12.61%
Revenue Next 2Y179.39%
Revenue Next 3Y118.28%
Revenue Next 5YN/A

3.3 Evolution

TNXP Yearly Revenue VS EstimatesTNXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
TNXP Yearly EPS VS EstimatesTNXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -500M -1B -1.5B

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TNXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNXP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNXP Price Earnings VS Forward Price EarningsTNXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNXP Per share dataTNXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K -1.5K

4.3 Compensation for Growth

A more expensive valuation may be justified as TNXP's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.33%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TNXP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (7/11/2025, 8:00:00 PM)

After market: 40.64 -0.23 (-0.56%)

40.87

-1.49 (-3.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-14 2025-08-14/amc
Inst Owners6.7%
Inst Owner Change0%
Ins Owners0.05%
Ins Owner Change2.87%
Market Cap299.17M
Analysts82.5
Price Target414.8 (914.93%)
Short Float %15.43%
Short Ratio1.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)55.66%
Min EPS beat(2)13.8%
Max EPS beat(2)97.53%
EPS beat(4)3
Avg EPS beat(4)-68.45%
Min EPS beat(4)-477.45%
Max EPS beat(4)97.53%
EPS beat(8)6
Avg EPS beat(8)-23.27%
EPS beat(12)9
Avg EPS beat(12)-8.68%
EPS beat(16)10
Avg EPS beat(16)-6.2%
Revenue beat(2)0
Avg Revenue beat(2)-17.14%
Min Revenue beat(2)-27.68%
Max Revenue beat(2)-6.61%
Revenue beat(4)0
Avg Revenue beat(4)-20.68%
Min Revenue beat(4)-38.15%
Max Revenue beat(4)-6.61%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-30.29%
EPS NQ rev (1m)-1.79%
EPS NQ rev (3m)98.98%
EPS NY rev (1m)-1.97%
EPS NY rev (3m)99.06%
Revenue NQ rev (1m)-1.89%
Revenue NQ rev (3m)-39.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-35.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.79
P/FCF N/A
P/OCF N/A
P/B 1.66
P/tB 1.66
EV/EBITDA N/A
EPS(TTM)-1963.61
EYN/A
EPS(NY)-6.36
Fwd EYN/A
FCF(TTM)-8.19
FCFYN/A
OCF(TTM)-8.19
OCFYN/A
SpS1.37
BVpS24.64
TBVpS24.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.4%
ROE -73.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.81%
FCFM N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.67%
Cap/Sales 0.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.31
Quick Ratio 11.64
Altman-Z 9.16
F-Score5
WACC9.96%
ROIC/WACCN/A
Cap/Depr(3y)1346.5%
Cap/Depr(5y)20638.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.51%
EPS Next Y99.47%
EPS Next 2Y41.33%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-2.14%
Revenue Next Year-12.61%
Revenue Next 2Y179.39%
Revenue Next 3Y118.28%
Revenue Next 5YN/A
EBIT growth 1Y31.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.02%
OCF growth 3YN/A
OCF growth 5YN/A